October 23, 2012 — A study found that a tailored therapy approach that adjusts the loading dose of clopidogrel according to measured platelet reactivity is superior to prasugrel therapy in reducing high platelet reactivity (a risk factor for worse outcomes) in patients with acute coronary syndrome (ACS). Results of the trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

October 23, 2012 — In the DEBATE-SFA trial, researchers found that the use of a paclitaxel drug-eluting balloon (DEB) to widen the artery prior to implanting a self-expanding nitinol stent yielded a lower restenosis rate after one year. Results of the trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

October 22, 2012 — W. L. Gore & Associates announced that the U.S. Food and Drug Administration (FDA) has approved the use of the new Gore septal occluder for inclusion in the Gore REDUCE clinical study.

At RSNA 2012, GE Healthcare will be showcasing a comprehensive portfolio of ultrasound products for use across a broad range of patient exam types. Among the products to be highlighted will be the newly enhanced Logiq E9, Logiq S8 and others in the LOGIQ family.

NEC Display Solutions of America announced the U.S. Food and Drug Administration (FDA) 510(k) market clearance of the 21.3-in MultiSync MD211G3 medical diagnostic, flat panel display for the displaying and viewing of digital mammography images for diagnosis by trained physicians.

QuantiaMD, the largest online physician community, and The International CardiOncology Society (ICOS) announced at the ICOS 6th annual meeting in Milan, Italy a partnership to launch the ICOS global physicians collaboration forum on QuantiaMD. This first-of-its-kind partnership brings together an emerging area of medicine with QuantiaMD’s dynamic clinical exchange to rapidly drive awareness, education and training around the cardiac implications of oncology treatments.


The Transcatheter Cardiovascular Therapeutics (TCT) conference showcases key advancements being made in interventional cardiology, focusing this year on the next generation of drug-eluting stents, bioresorbable stents, patent foramen ovale (PFO) therapy, transcatheter valve therapy and cardiac imaging technologies.

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced six-month clinical, IVUS (Intravascular Ultrasound), OCT (Optical Coherence Tomography) and angiographic data for its 15-patient First-In-Man clinical study of the fully bioresorbable drug-eluting scaffold, the DESolve Bioresorbable Coronary Scaffold System at a late-breaking trial session of EuroPCR in Paris.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now